Patent Licensing Considerations for Biologics under the BPCIA

Authors

  • Sheila Swaroop Knobbe Martens Olson & Bear LLP
  • Carol Pitzel Cruz Knobbe Martens Olson & Bear LLP

DOI:

https://doi.org/10.5912/jcb617

Abstract

Author Biographies

Sheila Swaroop, Knobbe Martens Olson & Bear LLP

Sheila Swaroop is a partner at Knobbe Martens Olson & Bear LLP, where she focuses her practice on litigation of intellectual property disputes. Her experience includes pre-litigation counseling, strategic enforcement, and litigation of disputes through trial and appeal. Ms. Swaroop has an undergraduate degree in molecular biology from Harvard University and a law degree from U.C. Berkeley. She has litigated patent disputes under the Hatch-Waxman Act on behalf of various pharmaceutical companies, and has also litigated a wide variety of other intellectual property disputes involving multi-jurisdictional litigation, litigation at the International Trade Commission, and concurrent Patent Office proceedings.

Carol Pitzel Cruz, Knobbe Martens Olson & Bear LLP

Carol Pitzel Cruz is a partner at the Seattle office of Knobbe Martens Olson & Bear LLP. Ms. Pitzel Cruz represents various clients in all aspects of intellectual property disputes, with a focus on patent litigation. Ms. Pitzel Cruz has an undergraduate degree in Chemistry from the University of Washington and a law degree from the George Washington University. She is experienced in the area of pharmaceutical litigation, especially litigation involving Abbreviated New Drug Applications under the Hatch-Waxman Act. Prior to law school, Ms. Pitzel Cruz worked in the biotechnology industry in Seattle, Washington.

Published

2013-07-01

Issue

Section

Articles